Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Vietnam’s Ha Tay Now an ASKA Group Company
January 18, 2021
- Janssen Files Imbruvica for Post-Transplant GVHD in Japan
January 18, 2021
- Taiho Sets Up Stand-Alone Subsidiary in Switzerland
January 18, 2021
- Chiome Licenses Anti-TROP-2 Antibodies to China Firm
January 18, 2021
- Zeria, Astellas Wind Up Copromotion for Acofide
January 18, 2021
- Only 1/338th the Number of Flu Patients in December 2020 vs December 2019: Survey
January 18, 2021
- Sawai Continues Shipment Control, Supply Suspensions for 5 Drugs on COVID-19, Recalls by Peers
January 18, 2021
- Towa, Nissin to Recall Dipyridamole Over PMD Law Violation by API Warehouse Operator
January 18, 2021
- Kolon Ordered Payment to Mitsubishi Tanabe over Cell Therapy License Deal
January 15, 2021
- Genmab Set for Stand-Alone Drug Development, Biz in Japan
January 15, 2021
- Kaken to Codevelop Novel Multi-Specific Antibody with Swiss Biotech
January 15, 2021
- Daiichi Sankyo’s DMD Therapy Shows Efficacy in Several Patients in PI/II
January 14, 2021
- Nichi-Iko Announces Yet Another Recall, 38 Products Added to Bring Total to 75
January 14, 2021
- EA Pharma/Kissei Prepping to File Ulcerative Colitis Drug on Positive Japan PIII
January 14, 2021
- More than 90% of Patients Will Visit Doctors as Planned despite Emergency Declared: Survey
January 14, 2021
- Astellas Launches Joint Research on Molecular-Targeted Radiotherapies with US Biopharma
January 14, 2021
- Taiho Licenses SHP2 Drug Discovery Program to US Merck
January 14, 2021
- Chugai Links Up with IBM to Go Digital in Manufacturing
January 14, 2021
- Sosei Pairs Up with UK’s AI-Powered Drug Discovery Firm
January 13, 2021
- Medipal to Take on Akalux Distribution in Japan, Rakuten’s Photoimmunotherapy
January 13, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…